{"id":6349,"date":"2019-07-18T09:33:20","date_gmt":"2019-07-18T13:33:20","guid":{"rendered":"https:\/\/www.cosprc.ca\/?post_type=cos-resource&#038;p=6349"},"modified":"2020-01-09T12:19:29","modified_gmt":"2020-01-09T17:19:29","slug":"sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019","status":"publish","type":"post","link":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/","title":{"rendered":"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire"},"content":{"rendered":"\n<p><em>(juillet 2019)<\/em><\/p>\n\n\n\n<p> <strong>Details d\u2019acc\u00e8s<\/strong> <\/p>\n\n\n\n<p>Lisez la version int\u00e9grale de l\u2019\u00e9nonc\u00e9 de principe de la Soci\u00e9t\u00e9 canadienne de la r\u00e9tine (SCR)<\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/cosprc.ca\/wp-content\/uploads\/2019\/07\/13c-Position-Paper-May-21-final_CRS_FR_logo.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire <\/a><a href=\"https:\/\/cosprc.ca\/wp-content\/uploads\/2019\/07\/13c-Position-Paper-May-21-final_CRS_FR_logo.pdf\" class=\"wp-block-file__button\" download> t\u00e9l\u00e9charger <\/a><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(juillet 2019) Details d\u2019acc\u00e8s Lisez la version int\u00e9grale de l\u2019\u00e9nonc\u00e9 de principe de la Soci\u00e9t\u00e9 canadienne de la r\u00e9tine (SCR)<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[305,315],"post_tag":[],"content_type":[],"class_list":["post-6349","post","type-post","status-publish","format-standard","hentry","category-pour-les-ophtalmologistes","category-retine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire - Practice Resource Centre<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire - Practice Resource Centre\" \/>\n<meta property=\"og:description\" content=\"(juillet 2019) Details d\u2019acc\u00e8s Lisez la version int\u00e9grale de l\u2019\u00e9nonc\u00e9 de principe de la Soci\u00e9t\u00e9 canadienne de la r\u00e9tine (SCR)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/\" \/>\n<meta property=\"og:site_name\" content=\"Practice Resource Centre\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-18T13:33:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-01-09T17:19:29+00:00\" \/>\n<meta name=\"author\" content=\"Fetun Delessa\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fetun Delessa\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\\\/\"},\"author\":{\"name\":\"Fetun Delessa\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/3fca208dd4d156beb92f181ee1629eb1\"},\"headline\":\"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire\",\"datePublished\":\"2019-07-18T13:33:20+00:00\",\"dateModified\":\"2020-01-09T17:19:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\\\/\"},\"wordCount\":60,\"articleSection\":[\"Pour les ophtalmologistes\",\"R\u00e9tine\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\\\/\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\\\/\",\"name\":\"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire - Practice Resource Centre\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\"},\"datePublished\":\"2019-07-18T13:33:20+00:00\",\"dateModified\":\"2020-01-09T17:19:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/3fca208dd4d156beb92f181ee1629eb1\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/\",\"name\":\"Practice Resource Centre\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cosprc.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/3fca208dd4d156beb92f181ee1629eb1\",\"name\":\"Fetun Delessa\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g\",\"caption\":\"Fetun Delessa\"},\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/author\\\/rs9ebny670cpwyyn\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire - Practice Resource Centre","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/","og_locale":"fr_FR","og_type":"article","og_title":"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire - Practice Resource Centre","og_description":"(juillet 2019) Details d\u2019acc\u00e8s Lisez la version int\u00e9grale de l\u2019\u00e9nonc\u00e9 de principe de la Soci\u00e9t\u00e9 canadienne de la r\u00e9tine (SCR)","og_url":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/","og_site_name":"Practice Resource Centre","article_published_time":"2019-07-18T13:33:20+00:00","article_modified_time":"2020-01-09T17:19:29+00:00","author":"Fetun Delessa","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Fetun Delessa"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/#article","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/"},"author":{"name":"Fetun Delessa","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/3fca208dd4d156beb92f181ee1629eb1"},"headline":"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire","datePublished":"2019-07-18T13:33:20+00:00","dateModified":"2020-01-09T17:19:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/"},"wordCount":60,"articleSection":["Pour les ophtalmologistes","R\u00e9tine"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/","url":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/","name":"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire - Practice Resource Centre","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/#website"},"datePublished":"2019-07-18T13:33:20+00:00","dateModified":"2020-01-09T17:19:29+00:00","author":{"@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/3fca208dd4d156beb92f181ee1629eb1"},"breadcrumb":{"@id":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cosprc.ca\/fr\/sustained-funding-to-ensure-access-to-anti-vascular-endothelial-growth-factor-drugs-2019\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cosprc.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Financement soutenu pour assurer l\u2019acc\u00e8s aux m\u00e9dicaments anti-facteur de croissance endoth\u00e9lial anti-vasculaire"}]},{"@type":"WebSite","@id":"https:\/\/www.cosprc.ca\/#website","url":"https:\/\/www.cosprc.ca\/","name":"Practice Resource Centre","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cosprc.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/3fca208dd4d156beb92f181ee1629eb1","name":"Fetun Delessa","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g","caption":"Fetun Delessa"},"url":"https:\/\/www.cosprc.ca\/fr\/author\/rs9ebny670cpwyyn\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-17 22:15:41","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/6349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/comments?post=6349"}],"version-history":[{"count":8,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/6349\/revisions"}],"predecessor-version":[{"id":8588,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/6349\/revisions\/8588"}],"wp:attachment":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/media?parent=6349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/categories?post=6349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/post_tag?post=6349"},{"taxonomy":"content_type","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/content_type?post=6349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}